Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day everyone and welcome to today’s Avadel Pharmaceuticals ...

Still, you largely own biotech stocks for the promise of their research and development (R&D) pipeline and the company's ...

In a recent discussion with Dr. Joe Dituri on Power Athlete Radio, we explored the significant risk posed by America’s dependence on foreign-made pharmaceutical ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

Robert F. Kennedy Jr. has vowed to combat "the chronic disease epidemic in this country" in the Trump administration, with ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals REGN. And retail traders should know. We noticed this today when the trades showed up on publicly ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...